Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Trial Details

NCT ID
NCT06607549
Phase
PHASE1
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Loncastuximab tesirine and rituximab (Lonca-R)
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Providence, Rhode Island, United States|41.82399,-71.41283
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Participant aged ≥ 18 years
  • ECOG Performance Status ≤ 3
  • Histologically confirmed primary CNS lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) with CNS involvement with either:
  • Relapsed or refractory disease with at least 1 prior therapy OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →